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Conclusions: IMRT planning achieves better dose coverage and 
homogeneity in comprehensive irradiation in breast cancer; however, 
it increases dose to carotid artery as compared to conventional 
3DCRT. Byspecifying dose constraint to the carotid artery, it is 
possible to reduce carotid artery doses in IMRT plans by improving 
dose conformity and homogeneity. It seems reasonable to designate 
carotid artery as a dose limited structure for long term survivors with 
high risks for vascular disorders.  
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Purpose/Objective: The purpose of the present study is to evaluate 
toxicity and cosmetic outcome in breast cancer survivors treated with 
hypo-fractionated adjuvant radiotherapy (HF-RT) and to identify risk 
factors for toxicity, with special focus on the impact of age, co 
morbidities and chemotherapy. For comparison, a group of 65 patients 
with similar characteristics and consecutively treated with 
conventional fractionation was retrospectively selected. 
Materials and Methods: From April 2010 and May 2012, 190 women 
with early breast cancer were treated with HF-RT, after conserving 
surgery. The patients received 40.05 Gy in 15 fractions. The boost to 
the tumour bed was administered with a total dose of 9 Gy in 3 
consecutive fractions in 50 women due to young age (< 50 yrs) or to 
positive margins. Physician-rated toxicity and cosmetic outcomes 
were prospectively assessed during yearly follow-up after 
radiotherapy.  
Results: In the HF-RT group, the mean age was 69 years. 11% and 32% 
patients were affected by diabetes mellitus and hypertension, 
respectively. 13% had tumors that were 2 cm or larger in diameter; 
pTis = 17%, pT1a= 6%, pT1b= 23%, pT1c=41%, pT2=13% ; 10% had 
estrogen-receptor–negative disease and 29 % had high-grade disease. 
Pre-operative chemotherapy was administered in 10 patients; 
adjuvant systemic therapy and hormone therapy were given in 19 
patients, while 11 and 115 patients received chemotherapy or 
hormone therapy alone, respectively. The mean follow-up was 19 
months (range 6-32 months). The median time from surgery was 29 
days, with overall median treatment duration of 22 days. At last 
follow up all patients are alive without local recurrence. By the end of 
RT 18% of the patients treated with HF-RT developed no toxicity, 
while 55.7% showed grade 1 and 13.3% grade 2 acute skin toxicity. 
Only one patient experienced a grade 3 acute skin toxicity. In the 
control group, early G1 reactions were observed in 24 patients (42%); 
19% of patients showed G2 acute toxicity and only one patient 
developed G3 acute reaction. Neither grade 4 skin ulceration nor soft 
tissue necrosis was observed. Late toxicity was assessed after 6 
months from RT completion in 120/190 patients in the 
hypofractionation group and in 51/65 patients in the standard RT 
group. Late toxicity according to the RTOG criteria was observed in 9 
patients (7.5%) in the HF-RT group and in 4 patients (8%) in the 
conventional fractionated radiation group. The difference was not 
statistically significant. Cosmetic result was assessed and scored at 
the RT end and 6 months later: at last follow up, 71% of women in the 
control-group as compared with 68.8% of the women in the HF-RT 
group had a good or excellent cosmetic outcome. 
Conclusions: Our results confirm the feasibility of the HF-RT with 2,67 
Gy/fx to a total dose of 40,05 Gy in patients with breast cancer. If 
compared with conventional RT group, the hypofractionation not 
seems to increase the late toxicity. Long-term follow up is need to 
confirm this finding. 
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Purpose/Objective: To analyze the treatment results of cN3 breast 
cancer patients who treated with neoadjuvant chemotherapy 
Materials and Methods: Between 2003 and 2009, Of 241 breast cancer 
patients who received neoadjuvant chemotherapy, 52 cN3 non-
inflammatory patients were included. Median age was 43 years (range 
25-75). Clinical T-stage were T1 (5.8%), T2 (38.5%), T3 (48.0%) and T4 
(7.7%). Clinical N-stage were N3a (11.5%), N3b (25.0%), and 
N3c(63.5%). N3 lesions were detected on PET-CT in 43 patients (82.7%) 
and confirmed histolotically in 30 patients (57.7%). Antracycline- 
and/or taxane-based neoadjuvant chemotherapy were delivered to 
98.1% of patients. Breast conserving surgery was enabled to 14 
patients (26.9%), others received mastectomy alone (59.6%) or 
mastectomy with immediate reconstruction (13.5%). Excision of N3 
lesion was performed in 18 patients (34.6%). Adjuvant radiation 
therapy were performed in 44 patients (84.6%), and 23 patients 
received radiation dose more than 50.4 Gy to N3 region. 
Results: Median follow-up period was 41 months. Actuarial four-year 
overall, disease-free, locoregional-recurrence-free survival rate were 
72.4, 49.1, and 70.7% respectively. Actuarial four-year control rate of 
N3 region was 74.6%. Univariate risk factor analysis revealed ypN 
stage and ypStage as significant risk factors for loco-regional, disease-
free, and over survival rate. Excisional biopsy and higher dose to N3 
region were proved not to be correlated with regional control rate. 
Conclusions: Neoadjuvant chemotherapy followed by curative 
resection and adjuvant radiation therapy accomplished comparable 
treatment results for regionally-advanced breast cancer patients. 
More patients and longer follow-up are mandatory to investigate the 
optimal locoregional treatment regimen after neoadjuvant 
chemotherapy. 
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Purpose/Objective: This study aims to estimate the dose received by 
the supraclavicular fossa (SCF) and levels I,II and III of the axilla in 
patients with breast carcinoma undergoing regional adjuvant 
radiotherapy using routine planning techniques. Dose to the brachial 
plexus was also evaluated. 
Materials and Methods: A CT-planning study of 24 patients was 
conducted. The BP and nodal target volumes were contoured and five 
treatment plans were generated for each patient. Treatment 
techniques included (i) standard tangential fields; (ii) high tangential 
fields (HTF); (iii) 3-field technique targeting the SCF; (iv) 3-field 
technique targeting the SCF and axilla level III; (v) technique targeting 
the full nodal region, the SCF and axilla levels I-III. Dose-volume 
histograms were used to evaluate the percentage volume of the target 
covered by the 95% isodose (V95%) to assess target coverage, and the 
maximum and mean dose to the brachial plexus and the volume of this 
organ at risk receiving 45,48, and 50Gy. 
Results: Using standard tangential fields V95% for axilla level I was 
39.6% and for level II was 2.7%. Using HTF the V95% for axilla level I 
was 90% and 55% for level II. Suboptimal coverage of the SCF target 
volume was noted for each of the three techniques targeting this 
volume. The mean maximum BP dose was 50.9Gy for treatment to the 
SCF alone, 51.1Gy for treatment to the SCF and axilla level III, and 
53.2Gy for full nodal treatment. The mean irradiated BP volume 
receiveg > 45Gy was 49.5%, 65.4% and 77.7% for these groups 
respectively. 
Conclusions: It is important to be aware of the expected coverage for 
axillary levels I-III when using common radiotherapy regimens 
particularly given the current controversy over axillary management. 
Using conventional tangential fields suboptimal coverage of level I was 
achieved and Level II received only a minimal dose. Axillary levels 
should be contoured in node positive patients and coverage should be 
documented. As with previous studies our study shows that routine 
radiation prescriptions do not optimally cover intended targets for 
every patient. The BP dose should be considered for patients 
undergoing full nodal treatment.  
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Purpose/Objective: The delineation of target and organs at risk 
(OARs) is a central part of the treatment planning of postoperative 
radiotherapy for breast cancer patients. We performed an 
investigation of the consequences of inter-observer variation in the 
delineation of the clinical target volume (CTV), heart and left anterior 
